Replimune Group, Inc. $REPL Holdings Trimmed by Braidwell LP

Braidwell LP lowered its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 71.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 422,887 shares of the company’s stock after selling 1,038,939 shares during the period. Braidwell LP owned approximately 0.54% of Replimune Group worth $3,929,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of REPL. US Bancorp DE raised its position in Replimune Group by 582.6% during the first quarter. US Bancorp DE now owns 4,594 shares of the company’s stock valued at $45,000 after buying an additional 3,921 shares during the period. Raymond James Financial Inc. purchased a new position in Replimune Group during the 2nd quarter valued at about $69,000. AlphaQuest LLC increased its holdings in shares of Replimune Group by 99.9% in the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company’s stock valued at $92,000 after purchasing an additional 4,925 shares during the period. Letko Brosseau & Associates Inc. acquired a new position in shares of Replimune Group in the 2nd quarter valued at about $100,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Replimune Group in the second quarter worth approximately $118,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $3.00 to $13.00 in a research report on Monday, October 20th. Piper Sandler upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a report on Monday, October 20th. Leerink Partnrs upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a research report on Monday. Finally, HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

Insider Buying and Selling

In other news, insider Konstantinos Xynos sold 7,248 shares of Replimune Group stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the transaction, the insider owned 139,685 shares of the company’s stock, valued at $1,271,133.50. This trade represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Christopher Sarchi sold 5,208 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $47,392.80. Following the completion of the sale, the insider owned 123,088 shares of the company’s stock, valued at $1,120,100.80. The trade was a 4.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 25,625 shares of company stock valued at $257,607 over the last 90 days. 5.20% of the stock is currently owned by insiders.

Replimune Group Trading Up 3.1%

Shares of NASDAQ:REPL opened at $10.18 on Friday. The stock has a market capitalization of $798.52 million, a PE ratio of -2.94 and a beta of 0.66. Replimune Group, Inc. has a 1 year low of $2.68 and a 1 year high of $14.80. The firm has a fifty day moving average price of $8.46 and a 200 day moving average price of $7.63. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.